{"entity":{"id":"itil-168","kind":"drug","name":"ITIL-168","aka":[],"tldr":"ITIL-168 is an autologous tumour-infiltrating lymphocyte cell therapy from Instil Bio that reached phase 2 for advanced cutaneous melanoma, cervical cancer and head and neck squamous cell carcinoma and other cancers; development has stopped.","summary":"ITIL-168 is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy from Instil Bio. A cell therapy made from the patient's own tumour-infiltrating lymphocytes, grown from a piece of resected tumour. Its furthest stage is phase 2, for advanced cutaneous melanoma, cervical cancer, head and neck squamous cell carcinoma and non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Instil's Form 10-K for 2025 (filed March 2026) says it discontinued its TIL programme and the ITIL-168 and ITIL-306 trials 'several years ago'. NCT05050006 (phase 2, melanoma) TERMINATED; NCT05393635 (phase 1, solid tumours) WITHDRAWN. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Instil Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976926000019/til-20251231.htm"},{"label":"Instil Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05050006"},{"label":"ClinicalTrials.gov: trials of ITIL-168","url":"https://clinicaltrials.gov/search?intr=ITIL-168"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["melanoma","cervical","head-and-neck","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["instil-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05050006","nct05393635"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ITIL-168","modality":"Autologous tumour-infiltrating lymphocyte (TIL) cell therapy","mechanism":"A cell therapy made from the patient's own tumour-infiltrating lymphocytes, grown from a piece of resected tumour.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/itil-168/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"instil-bio","kind":"company","name":"Instil Bio","route":"/companies/instil-bio/"}],"trial":[{"id":"nct05050006","kind":"trial","name":"ITIL-168 in Advanced Melanoma","route":"/trials/nct05050006/"},{"id":"nct05393635","kind":"trial","name":"ITIL-168 in Advanced Solid Tumors","route":"/trials/nct05393635/"}]}}